C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.690
+0.190 (7.60%)
At close: Mar 25, 2026, 4:00 PM EDT
2.610
-0.080 (-2.97%)
Pre-market: Mar 26, 2026, 8:56 AM EDT
C4 Therapeutics Employees
C4 Therapeutics had 104 employees as of December 31, 2025. The number of employees decreased by 6 or -5.45% compared to the previous year.
Employees
104
Change (1Y)
-6
Growth (1Y)
-5.45%
Revenue / Employee
$345,644
Profits / Employee
-$1,009,558
Market Cap
262.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | -6 | -5.45% |
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Cellectis | 222 |
| Coherus Oncology | 147 |
| Voyager Therapeutics | 141 |
| OmniAb | 89 |
| Editas Medicine | 87 |
| Rezolute | 75 |
| Camp4 Therapeutics | 48 |
CCCC News
- 1 day ago - C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 15 days ago - C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact - Seeking Alpha
- 16 days ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire